Stephens Lowers Medifast (NYSE:MED) Price Target to $12.00

robot
Abstract generation in progress

Stephens has decreased its price target for Medifast (NYSE:MED) to $12.00 from $15.00, while maintaining an “equal weight” rating, suggesting a potential 12% upside. This aligns with the consensus analyst rating of “Reduce” and an average price target of $12.00. Medifast recently reported better-than-expected revenue and EPS for the last quarter but remains unprofitable, issuing negative EPS guidance for both the full year 2026 and Q1 2026.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
0/400
No comments
  • Pin